Scarica l'app Stockscreener
25.79
2.10%
0.53
Precedente Chiudi:
$25.26
Aprire:
$25.28
Volume 24 ore:
486.98K
Relative Volume:
0.43
Capitalizzazione di mercato:
$1.85B
Reddito:
$81.26M
Utile/perdita netta:
$-102.66M
Rapporto P/E:
-18.86
EPS:
-1.3678
Flusso di cassa netto:
$-77.62M
1 W Prestazione:
+2.54%
1M Prestazione:
-5.01%
6M Prestazione:
-5.70%
1 anno Prestazione:
+52.42%
Intervallo 1D:
$25.28
$26.34
Intervallo di 1 settimana:
$25.00
$27.02
Portata 52W:
$16.00
$31.34
Zymeworks Bc Inc Stock (ZYME) Company Profile
Nome
Zymeworks Bc Inc
Settore
Industria
Telefono
302-274-8744
Indirizzo
108 PATRIOT DRIVE, SUITE A, MIDDLETOWN
Compare ZYME vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Bc Inc
|
25.79 | 1.85B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Bc Inc Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-29 | Iniziato | TD Cowen | Buy |
| 2026-09-17 | Iniziato | Wolfe Research | Outperform |
| 2026-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2026-06-09 | Ripresa | Truist | Buy |
| 2025-12-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Iniziato | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Ripresa | Wells Fargo | Equal Weight |
| 2025-10-14 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Bc Inc Borsa (ZYME) Ultime notizie
Jefferies keeps Buy on Zymeworks stock at USD 50 target - AD HOC NEWS
Zymeworks stock fell 2.14 percent as 2026 guidance reset - AD HOC NEWS
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook - TradingView
EBIT per share of Zymeworks Inc. – HAN:ZA8 - TradingView
CapEx per share of Zymeworks Inc. – HAN:ZA8 - TradingView
Taxes of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Nigeria
Citigroup keeps 'Buy' on Zymeworks after acquis... - Pluang
Zymeworks stock coverage reinstated at Buy by TD Cowen on acquisition - Investing.com Canada
Dilution adjustment of Zymeworks Inc. – HAN:ZA8 - TradingView
Zymeworks Inc. (ZYME) stock price, news, quote and history - Yahoo Finance UK
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Eyes Growth in COPD Market - GuruFocus
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - TradingView
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal - Benzinga
Zymeworks Completes Theravance Acquisition Deal - grafa.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. Updates Earnings Guidance for the Year 2026 - marketscreener.com
Zymeworks Inc. (ZYME) Theravance Biopharma, Inc.M&A CallSlideshow (NASDAQ:ZYME) 2026-09-28 - Seeking Alpha
Zymeworks Inc. and Theravance Biopharma, Inc. Acquisition Call Transcript - GuruFocus
Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Int - GuruFocus
Zymeworks Inc Expects Total Revenue, Including Collaboration Revenue From Yupelri, For 2026 To Be Between $278 Million And $292 Million - TradingView
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition - GlobeNewswire Inc.
Zymeworks Announces Updated 2026 Financial Guidance and - GlobeNewswire
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME - MarketBeat
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Zymeworks Completes Acquisition of Theravance Biopharma - GlobeNewswire
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks stock hits 52-week high at 30.75 USD - Investing.com
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Canada
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com India
ZJM stock holds near its latest trade. Zymeworks data still drives the setup - ad-hoc-news.de
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer - FinancialContent
Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - marketbeat.com
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright - MarketBeat
Zymeworks (ZYME), What Is Behind The Renewed Attention? - Yahoo Finance
Zymeworks shifts to revenue growth after FDA ap... - Pluang
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings - marketbeat.com
Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha
Zymeworks Bc Inc Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zymeworks Bc Inc Azioni (ZYME) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jeffrey T L Smith | Former Officer |
Mar 06 '26 |
Proposed Sale |
24.80 |
247,333 |
6,133,858 |
0 |
| Leone D Patterson | Former officer |
Feb 17 '26 |
Proposed Sale |
22.60 |
31,641 |
715,087 |
0 |
| Leone D Patterson | Former officer |
Feb 13 '26 |
Proposed Sale |
23.17 |
128,548 |
2,978,457 |
0 |
| Mark Hollywood | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
6,120 |
141,800 |
0 |
| Kenneth Galbraith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
30,424 |
704,924 |
0 |
| Paul Andrew Moore | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,560 |
221,505 |
0 |
| Jeffrey T L Smith | Officer |
Jan 12 '26 |
Proposed Sale |
23.17 |
9,310 |
215,713 |
0 |
| Hollywood Mark | EVP & Chief Operating Officer |
Jan 12 '26 |
Option Exercise |
0.00 |
17,666 |
0 |
139,033 |
| Hollywood Mark | EVP & Chief Operating Officer |
Jan 12 '26 |
Sale |
22.67 |
6,120 |
138,762 |
132,913 |
| Smith Jeffrey T L | EVP & Chief Medical Officer |
Jan 12 '26 |
Option Exercise |
0.00 |
17,666 |
0 |
36,018 |
3.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):